Evaluation of quantitative biosensor for glucose-6-phosphate dehydrogenase activity detection

Autoři: Pairat Pengboon aff001;  Areenuch Thamwarokun aff002;  Khaimuk Changsri aff003;  Chollanot Kaset aff003;  Sirinart Chomean aff003
Působiště autorů: Graduate Program in Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand aff001;  Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand aff002;  Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand aff003
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226927


Neonatal jaundice is a common and severe disease in premature infants with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency. The World Health Organization (WHO) has recommended screening for G-6-PD deficiency in newborns for early recognition as well as to prevent unwanted outcomes in a timely manner. The present study aimed to assess a point-of-care, careSTARTTM G6PD biosensor as a quantitative method for the diagnosis of G-6-PD deficiency. Factors influencing the evaluation of G-6-PD enzyme activity were examined in 40 adults, including ethylenediaminetetraacetic acid (EDTA) anticoagulant, hematocrit concentration, storage temperature and time. Analytic performance of the careSTARTTM G6PD biosensor was evaluated in 216 newborns and compared with fluorescent spot test (FST) and standard quantitative G-6-PD enzyme activity (SGT) assay. The results of factors affecting the G-6-PD enzyme activity showed that the activity determined from finger-prick was not statistically different from venous blood (p = 0.152). The G-6-PD value was highly dependent on the hematocrit and rose with increasing hematocrit concentration. Its activity was stable at 4°C for 3 days. Reliability analysis between the careSTARTTM G6PD biosensor and SGT assay showed a strong correlation with a Pearson’s correlation coefficient of 0.82 and perfect agreement by intraclass correlation coefficient (ICC) of 0.90. Analysis of the area under the Receiver Operating Curve (AUC) illustrated that the careSTARTTM G6PD biosensor had 100% sensitivity, 96% specificity, 73% positive predictive value (PPV), 100% negative predictive value (NPV) and 97% accuracy at 30% of residual activity. While the diagnostic ability for identifying G-6-PD deficiency had 78% sensitivity, 89% specificity, 56% positive predictive value (PPV), 96% negative predictive value (NPV) and 88% accuracy when stratified by gender. The careSTARTTM G6PD biosensor is an attractive option as a point-of-care quantitative method for G-6-PD activity detection. Quantification of G-6-PD enzyme activity in newborns is the most effective approach for the management of G-6-PD deficiency to prevent severe jaundice and acute hemolysis.

Klíčová slova:

Biosensors – Blood – Enzyme assays – Glucose-6-phosphate dehydrogenase deficiency – Hematocrit – Hemolytic anemia – Neonates – Primaquine


1. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64–74. doi: 10.1016/S0140-6736(08)60073-2 18177777

2. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the "old" and update of the new mutations. Blood Cells Mol Dis. 2012;48(3):154–65. doi: 10.1016/j.bcmd.2012.01.001 22293322

3. Monteiro WM, Val FF, Siqueira AM, Franca GP, Sampaio VS, Melo GC, et al. G6PD deficiency in Latin America: systematic review on prevalence and variants. Mem Inst Oswaldo Cruz. 2014;109(5):553–68. doi: 10.1590/0074-0276140123 25141282

4. Schrier SL. Human erythrocyte G6PD deficiency: pathophysiology, prevalence, diagnosis, and management. Compr Ther. 1980;6(7):41–7. 7471680

5. Abdul-Ghani R, Mahdy MAK, Saif-Ali R, Alkubati SA, Alqubaty AR, Al-Mikhlafy AA, et al. Glucose-6-phosphate dehydrogenase deficiency among Yemeni children residing in malaria-endemic areas of Hodeidah governorate and evaluation of a rapid diagnostic test for its detection. Malaria J. 2016;15.

6. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS One. 2018;13(11):e0206331. doi: 10.1371/journal.pone.0206331 30388146

7. Arese P, Gallo V, Pantaleo A, Turrini F. Life and Death of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Erythrocytes—Role of Redox Stress and Band 3 Modifications. Transfus Med Hemother. 2012;39(5):328–34. doi: 10.1159/000343123 23801924

8. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72(7):1277–82. 16225031

9. Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, et al. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. Tropical Medicine & International Health. 2004;9(5):615–23.

10. Fu C, Luo S, Li Q, Xie B, Yang Q, Geng G, et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. Sci Rep. 2018;8(1):833. doi: 10.1038/s41598-017-17667-6 29339739

11. Uthman OA, Graves PM, Saunders R, Gelband H, Richardson M, Garner P. Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies. Malar J. 2017;16(1):346. doi: 10.1186/s12936-017-1989-3 28830424

12. Uthman OA, Saunders R, Sinclair D, Graves P, Gelband H, Clarke A, et al. Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies. BMJ Open. 2014;4(5):e004664. doi: 10.1136/bmjopen-2013-004664 24833685

13. Lee SM, Geetha D. Dapsone induced hemolysis in a patient with ANCA associated glomerulonephritis and normal G6PD level and implications for clinical practice: case report and review of the literature. Springerplus. 2015;4:29.

14. WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale (Policy brief). Geneva: World Health Organization. 2016:28.

15. Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. New Engl J Med. 2019;380(3):215–28. doi: 10.1056/NEJMoa1710775 30650322

16. Anantasomboon P, Chanda M, Jugnam-ang W, Witoonpanich P, Cheepsunthorn P, Nuchprayoon I, et al. Evaluating the performance of automated UV enzymatic assay for screening of glucose 6-phosphate dehydrogenase deficiency. Int J Lab Hematol. 2019;41(2):192–9. doi: 10.1111/ijlh.12943 30383322

17. Fan YH, Lazenbery L, Foster E, Duelm F, Grant E Jr. Improved quantitative method for G6PD deficiency detection. J Clin Lab Anal. 2007;21(2):107–13. doi: 10.1002/jcla.20117 17385678

18. Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J. 2017;16(1):361. doi: 10.1186/s12936-017-2017-3 28893237

19. Nadarajan V, Shanmugam H, Sthaneshwar P, Jayaranee S, Sultan KS, Ang C, et al. Modification to reporting of qualitative fluorescent spot test results improves detection of glucose-6-phosphate dehydrogenase (G6PD)-deficient heterozygote female newborns. Int J Lab Hematol. 2011;33(5):463–70. doi: 10.1111/j.1751-553X.2011.01309.x 21501392

20. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391. doi: 10.1186/1475-2875-12-391 24188096

21. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient. Am J Trop Med Hyg. 2019;100(1):213–21. doi: 10.4269/ajtmh.18-0612 30350771

22. WHO. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. Geneva: World Health Organization. 2018:34.

23. Simundic AM. Measures of Diagnostic Accuracy: Basic Definitions. EJIFCC. 2009;19(4):203–11. 27683318

24. WHO. Technical Specifications Series for submission to WHO prequalification–diagnostic assessment: in vitro diagnostics medical devices to identify Glucose-6-phosphate dehydrogenase (G6PD) activity. Geneva: World Health Organization. 2016:20.

25. von Fricken ME, Weppelmann TA, Eaton WT, Masse R, de Rochars MVEB, Okech BA. Performance of the CareStart Glucose-6-Phosphate Dehydrogenase (G6PD) Rapid Diagnostic Test in Gressier, Haiti. Am J Trop Med Hyg. 2014;91(1):77–80. doi: 10.4269/ajtmh.14-0100 24778197

26. Boonpeng P. BB, Traivaree C, Changsri K. Molecular Characterization of G6PD Gene Mutation in Neonatal Jaundice in Phramongkutklao Hospital. RTA Med J. 2018;71(3):8.

27. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart (TM) G6PD Deficiency Screening Test, a Point-of-Care Diagnostic for Primaquine Therapy Screening. Plos One. 2011;6(12).

28. Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS One. 2014;9(12):e116143. doi: 10.1371/journal.pone.0116143 25541721

29. Lindblade KA, Mwololo K, van Eijk AM, Peterson E, Odhiambo F, Williamson J, et al. Evaluation of the WHO Haemoglobin Colour Scale for diagnosis of anaemia in children and pregnant women as used by primary health care nurses and community health workers in western Kenya. Trop Med Int Health. 2006;11(11):1679–87. doi: 10.1111/j.1365-3156.2006.01721.x 17054747

30. Marn H, Critchley JA. Accuracy of the WHO Haemoglobin Colour Scale for the diagnosis of anaemia in primary health-care settings in low-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2016;4(4):E251–E65. doi: 10.1016/S2214-109X(16)00005-X 26905314

31. Li MJ, Yang WC, Tai S, Hsu CL, Shao PL, Peng CT. The Reference Levels of Glucose-6-Phosphate Dehydrogenase Enzyme Activity for Infants in Taiwan. Blood. 2017;130.

32. Tang J, Zhou X, Liu X, Ning L, Zhou W, He Y. External quality assessment program for detection of glucose-6-phosphate dehydrogenase deficiency in the Guangxi region. Exp Ther Med. 2017;14(3):2021–4. doi: 10.3892/etm.2017.4761 28962119

33. Yan TZ, Cai R, Mo OH, Zhu DL, Ouyang H, Huang LH, et al. Incidence and complete molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Guangxi Zhuang autonomous region of southern China: description of four novel mutations. Haematol-Hematol J. 2006;91(10):1321–8.

34. Xu W, Wang J, Hua X, Du C. Detection of point mutations in exon 2 of the G6PD gene in Chinese G6PD variants. Chin Med Sci J. 1994;9(1):20–3. 8086629

Článek vyšel v časopise


2019 Číslo 12